Kura Oncology Inc (NASDAQ:KURA) has been given a consensus recommendation of “Buy” by the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $26.50.
KURA has been the topic of several recent research reports. Deutsche Bank decreased their price target on Kura Oncology from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Barclays increased their price target on Kura Oncology from $24.00 to $32.00 and gave the company an “overweight” rating in a report on Monday, August 31st. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Kura Oncology in a report on Friday, May 29th. Credit Suisse Group initiated coverage on Kura Oncology in a report on Tuesday, July 7th. They set an “outperform” rating and a $27.00 price target on the stock. Finally, Oppenheimer initiated coverage on Kura Oncology in a report on Sunday, May 31st. They set a “buy” rating and a $27.00 price target on the stock.
In other Kura Oncology news, CFO Marc Grasso sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $23.00, for a total value of $230,000.00. Following the completion of the sale, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $230,000. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Troy Edward Wilson sold 75,335 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $22.02, for a total transaction of $1,658,876.70. Following the completion of the sale, the chief executive officer now directly owns 28,096 shares of the company’s stock, valued at $618,673.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 127,857 shares of company stock valued at $2,833,247. 11.00% of the stock is owned by corporate insiders.
The coronavirus knocked the wind out of stocks. But there are 5 Companies that could be HUGE in 2020 and 2021! Time to get your FREE Report on these 5 Companies that could DOMINATE! (Tickers Included)
A number of institutional investors have recently added to or reduced their stakes in KURA. Macquarie Group Ltd. purchased a new stake in Kura Oncology in the 2nd quarter valued at about $31,000. FDx Advisors Inc. purchased a new stake in shares of Kura Oncology in the 1st quarter worth approximately $37,000. Great West Life Assurance Co. Can lifted its position in shares of Kura Oncology by 127.4% in the 2nd quarter. Great West Life Assurance Co. Can now owns 3,818 shares of the company’s stock worth $62,000 after purchasing an additional 2,139 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of Kura Oncology by 64.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,686 shares of the company’s stock worth $76,000 after purchasing an additional 1,833 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of Kura Oncology by 355.7% in the 1st quarter. Acadian Asset Management LLC now owns 7,693 shares of the company’s stock worth $77,000 after purchasing an additional 6,005 shares during the period. 92.88% of the stock is owned by institutional investors.
NASDAQ KURA opened at $24.12 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 18.45 and a current ratio of 18.45. The company has a market capitalization of $1.36 billion, a P/E ratio of -15.36 and a beta of 2.43. Kura Oncology has a one year low of $6.35 and a one year high of $25.12. The stock has a 50 day moving average price of $20.00 and a 200-day moving average price of $15.10.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.02. As a group, equities analysts predict that Kura Oncology will post -1.66 EPS for the current fiscal year.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Story: Stocks Increasing Dividends
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
According to Blackrock (NYSE:BLK) analysts, investors who are looking for growth as the economy begins to recover need to be in stocks. In fact, many investors are breathing a sigh of relief for not panicking when the market sold off in February and March.
But while a Black Swan event like the Covid-19 pandemic can teach investors short-term lessons, the trick to buy-and-hold investing is identifying companies that give you the confidence to invest for not just 10 weeks, but 10 years.
For many investors this means identifying key trends. Prior to the pandemic, trends were emerging. Those trends, such as e-commerce, financial technology, digital healthcare, are quickly becoming part of our “new normal.” Think about it. Cash is now literally “dirty money”. E-commerce is not just convenient, it’s essential. And we’ve figured out that the patient-doctor relationship can take place via videochat.
And all of this feeds into other trends, which includes the idea that our smartphones are only going to become more powerful, and more important. But the next 10 years are not destined to be the decade of stealth small-caps. Many of the companies that are well positioned for the next decade will be familiar to most investors.
Here are 7 companies that are going to become increasingly relevant over the next decade. When you buy them now, you’ll be thanking yourself when the calendar turns to 2030.